Vaginitis

Earn CME/CE in your profession:


Continuing Education Activity

Vaginitis is a common condition characterized by inflammation of the vagina, often resulting in symptoms such as itching, burning, discomfort, and abnormal discharge. This condition affects women at various life stages and can be caused by various factors, including infections, hormonal changes, and irritants. Common types of vaginitis include bacterial vaginosis, yeast infections, and trichomoniasis, each with distinct causes and treatments. Understanding the underlying cause is crucial for effective management and relief. Given its prevalence and impact on women's health, accurate diagnosis and treatment of vaginitis are essential for maintaining overall well-being and quality of life.

This activity is designed to provide healthcare professionals with the comprehensive knowledge to effectively diagnose, treat, and manage this common condition. Participants gain insights into the various types of vaginitis, understand their distinct etiologies, clinical presentations, and treatment protocols, and enhance their ability to differentiate between these conditions, prescribe appropriate therapies, and offer patient-centered care. This activity covers the latest advancements in diagnostic techniques and therapeutic options, preparing healthcare professionals to address the complexities of vaginitis. This activity also highlights the role of the interprofessional team in providing well-coordinated care to enhance patient quality of life.

Objectives:

  • Differentiate between the various types of vaginitis based on clinical presentation and diagnostic findings.

  • Identify common and uncommon causes of vaginitis using appropriate diagnostic tools.

  • Implement evidence-based treatment protocols tailored to the specific type of vaginitis.

  • Collaborate with an interprofessional healthcare team to develop strategies that enhance care coordination and improve outcomes for patients affected by vaginitis.

Introduction

Vaginal discharge, irritation, itching, and discomfort are common complaints of women at all stages of life. Vaginitis is an often-encountered condition that leads to millions of office visits annually, making it a frequent concern for clinicians. When evaluating a patient with a vaginal complaint, such as discharge or irritation, it is important first to understand the range of normal findings. Once a good understanding of normal is established, it is easier to recognize when a pathological process is present or requires treatment.[1][2] The balance of microorganisms in the vagina plays a critical role in maintaining a healthy environment for the body, particularly in terms of reproductive health. However, the definition of a normal versus an imbalanced state—referred to as dysbiosis—in the vaginal microbiome is still a topic of active discussion. This issue is particularly relevant as women from various ethnic backgrounds display different microbial compositions in their vaginas, which can also vary by region. Various factors such as pregnancy, menstrual cycle, sexual behavior, age, and contraceptive methods influence this dynamic microbial environment. Lactobacilli are the predominant bacteria in the vaginal flora of many women. These beneficial bacteria offer protective effects against potential pathogens, thus reducing the risk of urinary tract and sexually transmitted infections (STIs).[3]

Etiology

The vaginal epithelium is a hormone-responsive, nonkeratinized, stratified squamous epithelium. The normal vaginal flora of reproductive-age women includes multiple aerobic, facultative anaerobic, and obligate anaerobic species. Over 50 species of bacteria are normally present in the vagina, with lactobacilli predominating in most women.[3] Anaerobic bacteria dominate aerobes by a ratio of 10:1. The bacteria are symbiotic with the host and can change based on the vaginal microenvironment.[4][5][6] Worldwide, scientists have conducted studies to profile the vaginal microbiome of their region of the world, concluding that the normalcy of vaginal flora varies from one region to another.[3]

Normal Vaginal Flora

Gram-positive aerobes:

  • Lactobacillus
  • Diphtheroids
  • Staphylococcus aureus
  • S epidermidis
  • Group B Streptococcus
  • Enterococcus faecalis
  • Staphylococcus spp

Gram-negative aerobes:

  • Escherichia coli
  • Klebsiella species
  • Proteus species
  • Enterobacter species
  • Acinetobacter species
  • Citrobacter species
  • Pseudomonas species

Gram-negative anaerobes:

  • Prevotella species
  • Bacteroides species
  • Bacteroides fragilis species
  • Fusobacterium species
  • Veillonella species

Anaerobic gram-positive cocci:

  • Peptostreptococcus species
  • Clostridium species

Anaerobic gram-positive bacilli:

  • Lactobacillus species
  • Propionibacterium species
  • Eubacterium species
  • Bifidobacterium species
  • Actinomyces israelii 

The composition of the vaginal flora is responsible for the pH of the vagina. In prepubertal girls and postmenopausal women, the lack of estrogen leads to a deficiency of glycogen and, thus, a lack of lactic acid-producing flora. Lactobacillus species are deficient and have a high bacterial diversity. The normal prepubertal and postmenopausal vaginal pH is 6 to 7.5. Women can be prone to infections in these age ranges, as the only commensal flora is mainly of skin origin. In prepubertal girls, vulvovaginitis is the most common gynecological condition reported.

Vaginitis is much more common in women during their reproductive years.[7] Estrogen stimulates the production of glycogen in the vaginal mucosa. Glycogen is the nutrient necessary for many vaginal ecosystem species present in reproductive-age females, including Lactobacillus. The glycogen is metabolized to lactic acid, which contributes to the normal vaginal pH of 3.8 to 4.2. This acidity suppresses the overgrowth of infectious organisms such as Mobiluncus, Prevotella, and Gardnerella vaginalis. Differences in the prevalence and diversity of lactobacilli among healthy women of reproductive age vary globally.[3] 

Changing any element of the vaginal ecology can alter the characteristics of the vaginal bacteria. For example, changes in hormonal status during menopause, pregnancy, and breastfeeding can greatly shift the makeup of the vaginal flora. Menses can act as a nutrient base for some bacterial species, leading to their overgrowth, but there is no clear evidence that this is associated with pathogens or infection. Broad-spectrum antibiotic use can lead to alterations of the vaginal bacterial flora leading to Candida species overgrowth. Douching and unprotected vaginal intercourse can also increase the vaginal pH.[8][9] Vaginitis can be caused by the overgrowth of bacteria or yeast or an infection with trichomoniasis. In addition, irritants such as harsh soaps, scented hygiene products, and tight clothing may contribute to the development of vaginitis.[10]

Epidemiology

Vaginitis is a highly prevalent global condition that affects millions of women annually. Bacterial vaginosis is the most common cause, accounting for 40% to 50% of cases, followed by yeast infections, which affect about 20% to 25% of women at least once in their lifetime. Trichomoniasis, an STI, impacts approximately 8 million women annually in the United States.

The prevalence of vaginitis varies with age, sexual activity, and hormonal status, with an increased incidence noted in reproductive-aged women and during periods of hormonal change, such as pregnancy and menopause. The normal vaginal flora is constantly changing and is influenced by many physiological and environmental factors.[11] Socioeconomic factors, hygiene practices, and access to health care also influence the incidence and management of vaginitis. Approximately 8% to 18% of women report symptoms such as vaginal discharge, odor, pruritus, and discomfort yearly. Furthermore, 55% to 83% of women consult a healthcare professional when the symptoms occur, but most patients use over-the-counter antifungals as home therapy.[12][13] 

Bacterial Vaginosis

In reproductive-aged women, bacterial vaginosis is the most common cause of vaginitis. This condition is caused by a shift in normal vaginal flora, with lactobacilli being replaced by anaerobic bacteria. Because bacterial vaginosis is not an inflammatory condition, erythema, fissuring, and bleeding may not be present on physical examination.[14] Bacterial overgrowth of G vaginalis, Mycoplasma hominis, Mobiluncus spp., Bacteroides spp., Prevotella spp., Peptostreptococcus spp., Fusobacterium spp., and Porphyromonas spp. may be present. Symptoms include foul-smelling discharge, irritation around and outside the vaginal introitus, and, sometimes, burning with urination.[11] Please see StatPearls' companion reference, "Bacterial Vaginosis," for more information.

Vaginal Candidiasis

Candida vaginitis is caused by the overgrowth of Candida fungi, affecting 75% of women in their lifetimes. Candida infection is the next most common type of vaginitis after bacterial vaginosis, with 55% of women experiencing an infection by age 25. Approximately 9% of women report four or more episodes annually. Please see StatPearls' companion reference, "Vaginal Candidiasis," for more information.

Trichomoniasis

Trichomonas vaginalis is a protozoan parasite responsible for causing trichomoniasis, the most common nonviral STI worldwide. Over 1 million people in the United States are affected by this parasite annually. The global incidence of trichomoniasis infections is reported at 153 million cases. Age, race, income, socioeconomic factors, and education level contribute to the epidemiology of trichomoniasis globally.[15] Please see StatPearls' companion reference, "Trichomoniasis," for more information.

Desquamative Inflammatory Vaginitis 

The exact cause of desquamative inflammatory vaginitis is not well understood, but it involves significant inflammation of the vaginal epithelium. This infrequent, noninfectious, chronic inflammatory condition is more common in White women.[16] There may be an imbalance in the normal vaginal flora, with a significant decrease in Lactobacillus species and an overgrowth of other facultative anaerobic bacteria, resulting in an elevated vaginal pH.[17] Signs and symptoms of desquamative inflammatory vaginitis include profuse, copious, purulent vaginal discharge, often yellow or greenish and sometimes mixed with blood. Additional findings may include intense itching and burning sensation or even pain in the vulvovaginal area, redness and swelling of the vulvovaginal tissues, and dyspareunia.[16] 

Atrophic Vaginitis

Genitourinary syndrome of menopause is the new term for vulvovaginal atrophy, a condition that affects a significant percentage of menopausal women. Signs and symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, vaginal inflammation, burning, thin vaginal mucosa, loss of rugae, and, occasionally, purulent discharge. Wet mount microscopy of the vaginal discharge shows many white blood cells (WBCs), occasional parabasal and basal cells, decreased lactobacilli, and increased gram-positive cocci and gram-negative rods. Vaginal pH is frequently >4.5.[14]

Cytolytic Vaginitis

There is insufficient evidence to validate cytolytic vaginitis as a clinical entity, although this entity has been described since 1991. This type of vaginitis is associated with vaginal acidity that causes irritation and discharge due to high concentrations of Lactobacillus species.[18]

Mixed Vaginitis

Mixed vaginitis is the presence of two or more types of vaginal pathogens simultaneously.[19] Symptoms may be atypical, and treatment is more complicated than vaginitis from a single source. Mixed vaginitis has not been well-studied. A literature review revealed that the prevalence of mixed vaginitis varies widely, ranging from slightly over 4% to approximately 35%. Most commonly, bacterial vaginosis and candida are considered. However, study results have shown that the 3 most common types of mixed vaginitis include desquamative inflammatory vaginitis/atrophic vaginitis/bacterial vaginosis, vulvovaginal candidiasis plus desquamative inflammatory vaginitis/atrophic vaginitis, and vulvovaginal candidiasis plus bacterial vaginosis.[20]

Mycoplasma and Ureaplasma 

Neither the Centers for Disease Control and Prevention (CDC) nor the European STI guidelines advise conducting testing for Mycoplasma and Ureaplasma, as they have not been definitively linked to vaginitis and are typically associated only with their frequent co-occurrence with bacterial vaginosis. M genitalium may be an exception, as it can be associated with pelvic inflammatory disease and cervicitis, but testing for this should be reserved for recurrent or refractory cases.[18]

Pathophysiology

Vaginitis is inflammation of the vagina, typically caused by infections, hormonal changes, or irritants. The pathophysiology of vaginitis varies by type, but common symptoms include vaginal discharge, itching, burning, and changes in vaginal pH. The specific nature of the discharge and associated symptoms aid in distinguishing between different types of vaginitis. Accurate diagnosis relies on patient history, physical examination, and laboratory testing. Correct diagnosis of vaginitis cannot be accomplished over the phone.[18]

Histopathology

Vaginitis can be classified as either inflammatory or noninflammatory. In inflammatory vaginitis, microscopy of vaginal discharge reveals polymorphonuclear neutrophils, and physical examination shows erythema and edema. Noninflammatory vaginitis is associated with odor and discharge but not inflammatory changes.[14]

History and Physical

Obtaining a detailed history and performing a thorough physical examination are essential for diagnosing vaginitis. These steps help identify the underlying cause and guide appropriate treatment. During the patient evaluation, key elements must be considered to ensure a comprehensive symptom assessment and diagnostic approach.

Normal Vaginal Secretions

Normal vaginal secretions serve to keep the vagina healthy and maintain its pH balance by removing dead cells and bacteria. Normal physiological vaginal discharge varies in appearance, consistency, and volume throughout the menstrual cycle. Typically, vaginal secretions are clear to white and differ in consistency from watery to slightly thick and mucous-like, with a mild odor. During ovulation, the discharge becomes more abundant, clear, and stretchy, aiding in fertility. The normal vaginal pH is between 3.8 and 4.5; this pH level helps maintain an acidic environment that prevents infections.[21] Normal discharge should not cause itching, burning, or irritation. Significant color, consistency, odor, or symptom changes may indicate an infection or other issue warranting medical evaluation.

History

Symptoms prompting evaluation include reports of abnormal vaginal discharge, itching, vaginal irritation, odor, dysuria, and dyspareunia. The evaluation should start with a detailed patient history, focusing on the nature and timing of the symptoms. The patient should be asked about any previous episodes of similar symptoms and vulvovaginal hygiene practices, including the use of lubricants, shaving, and douching. A comprehensive sexual history, noting any previous STIs, should be obtained, and potential new allergen exposures should be investigated. Documenting any self-treatment attempts is essential. Finally, clinicians must review the medical history for immune suppression and other relevant medical conditions.[22] 

Physical Examination

The physical examination should begin with thoroughly evaluating the vulva and adjacent skin, looking for vulvar erythema, signs of dermatoses, ulcers, fissures, and edema. The appearance of the vaginal discharge should be noted, although visual characteristics alone are not diagnostic. Testing of the vaginal pH should be completed by sampling the vaginal discharge from the midportion of the vaginal sidewall because cervical mucus, semen, and blood may falsely elevate the pH.[22]

Evaluation

In-office diagnostic procedures for identifying the probable cause of vaginal symptoms involve several tests, including pH testing, a potassium hydroxide (KOH) whiff test, and microscopic examination using 0.9% saline and a 10% KOH solution. In addition, commercially available tests approved by the United States Food and Drug Administration (FDA) may be used to diagnose vaginitis.[22] A molecular assay obtains the most accurate diagnosis; however, microscopy allows for visualizing WBCs and parabasal cells observed in desquamative inflammatory vaginitis and genitourinary syndrome of menopause, respectively.[18]

Gold-Standard Tests

  • T vaginalis: Nucleic acid amplification test
  • Bacterial vaginosis: Multi-organism polymerase chain reaction (PCR)-based test
  • Vaginal candidiasis: Polymerase chain reaction (PCR)-based test or fungal culture

Wet Mount Microscopy

The optimal sampling location for vaginal discharge remains unclear, with variations in results depending on the site sampled. Sampling from the posterior vaginal fornix may pose disadvantages due to exposure to cervical secretions, resulting in higher pH and an increased likelihood of inflammatory cells. Recent research suggests that sampling from multiple vaginal sites, particularly the lower third of the vagina and anterior fornix, may improve detection rates for different vaginal conditions. Touching the uterine cervix during sampling should be avoided, as cervical mucus contamination can be identified by the presence of abundant leukocytes arranged in rows.[23] Ideally, a specimen collection is performed using an endocervical brush, a plastic spatula, or a Dacron swab. Cotton swabs are not ideal, as they can leave fibers behind. A thin layer of discharge is crucial for diagnostic purposes to enhance visualization. Different methods may be employed, with some clinicians placing a tiny drop of saline on a slide and mixing it with a small amount of vaginal discharge. In contrast, other clinicians spread the discharge evenly on the slide and then add a drop of saline.[23] Patient-collected specimens have recently been shown to be as accurate as provider-collected.[24] Next, a cover slip is carefully placed on the edge of the sample to prevent air bubbles, and then it is slid into place. Excess saline should be removed with absorbent paper. In addition, some clinicians prepare another glass slide with a droplet of 10% KOH to improve the identification of fungal structures by destroying epithelial cells. The slide should be viewed within 10 min of the collection because cooling limits the mobility of trichomonads. The 400× magnification is used to count organisms and cells per high-power field.[23]

  • Squamous epithelial cells are polygonal in shape, with a central nucleus approximately the size of a red blood cell (RBC). These cells have abundant, irregular cytoplasm, and their margins are well-defined. Squamous epithelial cells are present in large numbers in the vaginal secretions of healthy women.
  • Clue cells are an abnormal variation of the squamous epithelial cell. These cells are granular and irregular, characterized by coccobacillus bacteria attached in clusters to the cell surface, which makes the cells' edges stippled and borders indistinct. When present in abundance (>20% of squamous epithelial cells), clue cells indicate G vaginalis overgrowth.
  • WBCs appear one-half to one-third of the size of squamous epithelial cells. These cells exhibit a granular cytoplasm. The multi-lobed nucleus lends to the name polymorphonuclear leukocytes. In normal secretions, they are present in small numbers. A >3% count of WBCs suggests vaginal candidiasis, atrophic vaginitis, or infections with Trichomonas, chlamydia, gonorrhea, or herpes simplex virus.
  • RBCs are one-half the size of WBCs and are smooth, non-nucleated biconcave disks. These may be mistaken for yeast cells; however, RBCs are lysed by potassium hydroxide (KOH), whereas yeast cells remain visible on a KOH mount.
  • Parabasal cells are larger than a WBC but smaller than squamous epithelial cells. These cells are round to oval in shape with a nucleus-to-cytoplasm ratio of 1:1 or 1:2. The cytoplasm contains basophilic granulation or amorphic basophilic structures. These cells are rarely observed in normal vaginal secretions except during menstruation or in postmenopausal women. Parabasal cells, along with many WBCs, indicate desquamative inflammatory vaginitis. Basal cells are roughly the same size as WBCs but with round nuclei. The nucleus-to-cytoplasm ratio is 1:2. These cells are not typically found in vaginal secretions. Their presence can indicate vaginal atrophy or in the presence of excessive WBCs, desquamative inflammatory vaginitis.
  • Lactobacillus species are the predominant organism in a healthy reproductive-age vagina. These species appear as large, nonmotile rods.
  • T vaginalis is a flagellated protozoan slightly larger than a WBC. There are 4 anterior flagella and an undulating membrane that extends half the body length. An axostyle bisects the trophozoite longitudinally and protrudes from the posterior end. This configuration enables the organism to attach to the vaginal mucosa. As many as 70% of women infected with Trichomonas have no symptoms. When discharge is present, it is described as yellow to green and frothy, with a pH >4.5. The cervix may have a punctate, strawberry appearance.[14]
  • Yeast cells (blastospores) are similar in size to RBCs. Pseudohyphae are multiple buds that form chains instead of detaching. Yeast is best visualized under a 10× objective lens.

A separate slide is used for the KOH preparation. The saline-diluted specimen is added to the slide along with a drop of 10% KOH. Increased numbers of anaerobic bacteria, such as G vaginalis, Mobiluncus, and Trichomonas, rather than a predominance of predominance of lactobacilli, results in the production of amines. KOH causes the volatilization of these amines, resulting in a characteristic fishy odor, which is the basis for the whiff test. After the whiff test, the coverslip should be placed, and the slide should be left to rest for 5 min. This resting period allows the epithelial cells and the RBCs to dissolve. The microscopic exam can then be performed to search for yeast pseudohyphae and blastospores without interference from other cell types.

Gram Stain

Gram stain remains the gold standard for identifying the causative agent of bacterial vaginosis, but it is only routinely used in research. The Gram stain slide must be heat-fixed and evaluated using the Nugent score, which is calculated based on the observed quantities of Lactobacillus acidophilus, G vaginalis, Bacteroides species, and Mobiluncus species.

Cultures

Cell culture is limited in evaluating vaginitis and should not be used for diagnostic purposes.[18] Culture remains the gold standard for detecting yeast. Unfortunately, the results are not timely. The culture of G vaginalis is not useful as it is part of the normal flora in 50% of women. T vaginalis can be cultured, but it requires a specific medium, the Diamond medium, and is time-consuming and labor-intensive. Beyond recurrent yeast, culture is not clinically important in evaluating vaginitis.

DNA Technologies

DNA hybridization probes for G vaginalis, Candida species, and T vaginalis are used increasingly in the evaluation of abnormal vaginal discharge. The sensitivities are very high, and the turnaround is quick. Various point-of-care tests for T vaginalis and G vaginalis are commercially available. Most require in-house equipment, except OSOM® for trichomonas, which has the lowest sensitivity. These tests typically provide results within 15 to 60 min, with sensitivities of 90% or higher.[25][26][27]

Desquamative Inflammatory Vaginitis

Desquamative inflammatory vaginitis is a purulent vaginitis that is difficult to differentiate from other forms of inflammatory vaginitis and is often a diagnosis of exclusion.[14] Physical examination shows inflammation, discharge, and desquamation. Wet mount microscopy may show parabasal cells, an abundance of inflammatory cells, and the absence or significant reduction of lactobacilli. Vaginal pH is typically elevated (>4.5), and the amine test is negative.

Atrophic Vaginitis

Signs and symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, vaginal inflammation, thin mucosa, loss of rugae, pale and flattened vulvovaginal tissue, petechiae, and, occasionally, purulent discharge.[18][28] Wet mount microscopy shows large WBCs, occasional parabasal and basal cells, decreased lactobacilli, and increased gram-positive cocci and gram-negative rods. The vaginal pH is 5.0 to 5.5 or greater. No pathogens are present. More than 1 WBC per epithelial cell is observed on wet prep. Parabasal cells are present, and superficial vaginal cells are decreased in quantity or even absent.[17]

Mixed Vaginitis

The symptoms of mixed vaginitis may vary from person to person and are not specific. Patients with mixed vaginitis experienced a range of symptoms. The most commonly reported issues are alterations in discharge, such as changes in color, consistency, and odor; genital itching; and a burning sensation.[20]

Treatment / Management

Effective treatment of vaginitis requires a targeted approach based on the specific underlying cause. The various therapeutic options tailored to manage and resolve different types of vaginitis are outlined.

Recommended Regimens According to the Centers for Disease Control and Prevention

Bacterial vaginosis:

  • Metronidazole 500 mg orally twice daily for 7 days
  • Metronidazole gel 0.75%, 1 full applicator (5 g) intravaginally, once daily for 5 days
  • Clindamycin cream 2%, 1 full applicator (5 g) intravaginally at bedtime for 7 days [14]

Alternative regimens for bacterial vaginosis:

  • Tinidazole 2 g orally once daily for 2 days
  • Tinidazole 1 g orally once daily for 5 days
  • Secnidazole 2 g orally as a single dose
  • Clindamycin 300 mg orally twice daily for 7 days
  • Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days

Patients are no longer advised to abstain from alcohol use during treatment with metronidazole, as the disulfiram-like reaction has not been supported by evidence.[29] Approximately 80% to 90% cure rates are expected 1 week after treatment. No routine follow-up is necessary for the asymptomatic patient after treatment, although 30% recur at 3 months or later. With recurrent disease, defined as 3 episodes in 1 year or 2 episodes in 6 months, the first step is to confirm the diagnosis of bacterial vaginosis again. For recurrence, women can be treated with the same regimen again or use an alternative regimen. Multiple recurrences after completion of a recommended regimen can be treated with 0.75% metronidazole gel twice weekly for 3 months. Although this has been shown to reduce recurrences, the benefit does not persist when suppressive therapy is discontinued. Another option for persistent or recurrent disease that is not FDA-approved is an oral nitroimidazole followed by intravaginal boric acid 600 mg daily for 14 to 21 days and then suppressive 0.75% metronidazole gel twice weekly for 4 to 6 months.[14][18]

The CDC does not recommend oral or vaginal probiotics. Although vaginally delivered L crispatus may be a potential option, it is not FDA-approved. Condom use during treatment can be considered, though treating male partners is generally not advised. Topical clindamycin for male partners may hold promise, and treating symptomatic female partners is a reasonable approach.[18]

Trichomoniasis:

  • Metronidazole 500 mg orally twice per day for 7 days
  • Alternatively,
    • Tinidazole 2 gm orally once
    • Metronidazole 2 gm orally once
    • Secnidazole 2 gm orally once

Nitroimidazoles are the only class of antimicrobial medications effective against T vaginalis infections. The United States FDA cleared metronidazole and tinidazole for the oral or parenteral treatment of trichomoniasis. Metronidazole gel does not reach therapeutic levels in the urethra, vagina, and paravaginal glands and is not recommended for the treatment of trichomoniasis.[14] Tinidazole is avoided during pregnancy and contraindicated in the first trimester. The recommended metronidazole regimens have cure rates of approximately 84% to 98%, and the tinidazole regimen has rates of approximately 92% to 100%. Metronidazole resistance occurs in 4% to 10% of cases of vaginal trichomoniasis, and tinidazole resistance in 1%, but most cases of persistent infection are from reinfection. If routine treatment regimens fail, referral to an infectious disease specialist and susceptibility testing should be considered.[24]

The CDC treatment guidelines changed in 2021, and now trichomoniasis is the first STI for which the recommended treatment varies by anatomical sex. This change was based on an efficacy of 81% compared with 89% with the longer course of metronidazole in women. Any sexual partner in the 90 days before diagnosis should also be treated. For male partners, a single dose of metronidazole is still first-line, and condom use is recommended until all partners have been treated. The CDC does recommend a test of cure in 3 months.[18]

Yeast vulvovaginitis: Yeast vulvovaginitis is often secondary to C albicans, but less common pathogens include C glabrataC parapsilosisC tropicalis, and C krusei. Although Candida is a standard component of the vagina, risk factors for pathogenic overgrowth include antibiotic use, combination oral contraceptives, estrogen therapy, pregnancy, diabetes mellitus, corticosteroid use, and all forms of immune compromise. The infection is most common during the childbearing years when estrogen is plentiful. Glycogen is key to facilitating Candida growth and adherence. Signs and symptoms of yeast vulvovaginitis include genital burning, pruritis, dyspareunia, dysuria, and a thick, white, curd-like discharge. The wet prep is 60% to 70% sensitive to yeast vaginitis. Budding yeasts, pseudohyphae, large numbers of WBCs, lactobacilli, and clumps of epithelial cells are observed on the wet mount. The pH is <4.5, and the amine whiff test is negative. A yeast culture is rarely needed but can be ordered if non-C albicans species are suspected. C glabrata does not form pseudohyphae and is difficult to recognize on microscopy. DNA testing is also available to identify species.

Uncomplicated candida vaginitis: For uncomplicated vulvovaginal candidiasis, a short course (1- or 3-day course) of over-the-counter topical antifungals, such as clotrimazole, miconazole, tioconazole, butoconazole, and itraconazole, results in cure rates of 80% to 90%. A single oral dose of fluconazole 150 mg is also effective; however, fluconazole should not be used at any time during pregnancy or in possibly pregnant patients, due to the increased risk of spontaneous abortion and potentially other complications.[18] If the symptoms resolve, no follow-up is needed. There are no behavioral interventions, including changing contraceptive methods, that are supported by good data to reduce candidiasis infections.

Complicated candida vaginitis: Recurrent vulvovaginal candidiasis is defined as 2 episodes in 6 months or 3 episodes over 1 year. Treatment for recurrent candidiasis includes a course of 7 to 14 days of topical therapy, or a 100, 150, or 200 mg oral dose of fluconazole every third day for 3 doses (days 1, 4, and 7) can be used. The first-line maintenance regimen is oral fluconazole at dosages 100, 150, or 200 mg weekly for 6 months. Approximately 30% to 50% of women have recurrent disease after maintenance therapy is discontinued.

  • Severe candidiasis: A 7- to 14-day topical azole or 150 mg of fluconazole in 2 sequential oral doses 72 hours apart is often effective.
  • Non-C albicans candidiasis: A 7- to 14-day regimen of a non-fluconazole azole (oral or topical) as first-line therapy can be prescribed. If recurrence occurs, 600 mg of boric acid in a gelatin capsule is recommended, administered vaginally once daily for 2 weeks.

Desquamative inflammatory vaginitis: Treatment involves topical steroids to reduce inflammation, although randomized trials have not been completed. If bacterial overgrowth is suspected, clindamycin or other antibiotics may be prescribed. Initial therapy with 2% clindamycin cream vaginally every other night for 2 weeks can be tried. Alternatively, 100 mg hydrocortisone suppositories nightly for 3 weeks are suggested. Prolonged therapy with once- or twice-weekly medications for up to 2 months may be needed.[14][18] Topical estrogen therapy can be beneficial, particularly in postmenopausal women. Desquamative inflammatory vaginitis can be a chronic condition that requires long-term management. Patients may experience periods of relapse and remission. Regular follow-up with a healthcare professional is essential for managing symptoms and adjusting treatment.[17]

Genitourinary syndrome of menopause (atrophic vaginitis): Many women do not seek evaluation or therapy for atrophic vaginitis, although it can significantly affect sexual health and quality of life.[17] This condition is initially treated with lubricant use during intercourse and personal vaginal moisturizers. If these remedies do not give satisfactory results, then local vaginal estrogen therapy using a cream, suppository, or vaginal ring (7.5 μg dose) can be used. Intravaginal dehydroepiandrosterone is also an available treatment.[28] Vaginal treatment with radiofrequency and lasers is not recommended due to lack of efficacy studies.[17] More recently, a selective estrogen receptor agonist called ospemifene has been approved for use in patients with vulvovaginal atrophy of menopause; this medication is taken once daily by mouth at a dose of 60 mg. This medicine is an estrogen agonist in the vulvovaginal tissue and specifically promotes epithelial lining proliferation in this tissue.[30]

Mixed vaginitis: Mixed vaginitis is challenging to treat, and standard treatment regimens have not been established. Recurrence is common. Each pathogen requires treatment for complete eradication of vaginitis that is caused by two or more vaginal pathogens.[20] Several small clinical studies have shown the efficacy and safety of topical fenticonazole as a treatment for mixed bacterial and fungal vaginitis as an alternative to multiagent treatment regimens.[19]

Negative tests: If initial testing is negative, retesting during heightened symptoms may be appropriate. Patients should avoid self-treatment for at least 2 weeks before undergoing testing. Further evaluation may include allergy testing or biopsy if indicated. Reassurance can be provided, with the option to retest if symptoms worsen or recur.[18]

Differential Diagnosis

When evaluating a patient with vaginitis symptoms, it is crucial to consider a wide range of differential diagnoses. The following list encompasses various conditions that can mimic vaginitis. These differential diagnoses help ensure accurate diagnosis and appropriate management.

Sexually Transmitted Infections 

  • Chlamydia and gonorrhea: These infections can cause vaginal discharge, irritation, and discomfort similar to vaginitis.
  • Herpes simplex virus: Genital herpes can cause pain, itching, and vesicles, which might be mistaken for vaginitis.
  • Human papillomavirus: Some strains cause genital warts and changes in vaginal discharge.

Urinary Tract Infections 

Urinary tract infections can cause burning, urgency, and frequency of urination, which may be confused with the symptoms of vaginitis.

Pelvic Inflammatory Disease

Pelvic inflammatory disease can cause lower abdominal pain, fever, and unusual vaginal discharge, overlapping with vaginitis symptoms.

Dermatologic Conditions

  • Lichen sclerosus and lichen planus: These chronic skin conditions can cause itching, discomfort, and changes in the vulvar skin that may be mistaken for vaginitis.
  • Eczema and psoriasis: These entities can cause irritation and itching in the genital area.
  • Vulvodynia: Chronic pain or discomfort around the vulva can be mistaken for the discomfort associated with vaginitis.
  • Allergic reactions to products such as soaps, detergents, or feminine hygiene products can cause irritation and discharge similar to vaginitis.

Foreign Bodies

Retained tampons or other foreign objects can cause vaginal discharge, odor, irritation, and infection.

Prognosis

In most women, vaginitis has an excellent outcome, and a cure is likely. Most cases of vaginitis, including bacterial vaginosis, yeast infections, and trichomoniasis, respond well to medication, such as antibiotics or antifungals, depending on the underlying cause. However, recurrence is common and can lead to excoriations, chronic irritation, and scarring. In addition, these symptoms also lead to low libido and a decline in sexual function. Both emotional stress and psychosocial issues are not uncommon.[31][32] Certain risk factors, such as immunocompromised conditions or repeated irritant exposure, may affect the prognosis and recurrence. Early diagnosis and prompt treatment are crucial for achieving a favorable prognosis and preventing complications.

Atrophic vaginitis as part of genitourinary syndrome of menopause affects up to 77% of women, worsens over time, and persists lifelong. Local therapies, as discussed, improve symptom severity by up to 80%, and the prognosis is excellent with continued treatment.[28] 

Desquamative inflammatory vaginitis, however, is a chronic process that is difficult to diagnose and does not respond well to currently known therapies. The cure rate is under 35% at 2 years. Relapse is common, and continued therapy may be needed in over 50% of affected women.[16] 

Complications

If left untreated or improperly managed, vaginitis can lead to several complications. These complications include pelvic inflammatory disease, which can result from untreated bacterial vaginosis or STIs, such as trichomoniasis, leading to chronic pelvic pain, ectopic pregnancy, and infertility. Vaginitis also increases the risk of contracting and transmitting STIs, including HIV, by disrupting the normal mucosal barrier and immune defenses. In pregnancy, infections such as bacterial vaginosis and trichomoniasis are associated with preterm labor, low birth weight, and amniotic fluid infection (chorioamnionitis), posing risks to both the mother and the baby.

Chronic vaginitis can cause persistent symptoms such as itching, burning, and discomfort, affecting daily activities and sexual intercourse, leading to distress and relationship issues. Recurrent inflammation and irritation can damage vulvar and vaginal tissues, increasing susceptibility to other infections and skin conditions. Psychosocial impacts, including anxiety, depression, and decreased sexual confidence, can also occur. Misdiagnosis or incorrect treatment may exacerbate symptoms and lead to unnecessary antibiotic use, contributing to resistance. Therefore, proper diagnosis, timely treatment, and preventive measures are essential to avoid these complications.

Consultations

Patients with vaginitis may require consultations with specialists depending on the complexity or severity of their condition. Gynecologists are often consulted for cases refractory to initial treatment, recurrent infections, or when underlying gynecological issues are suspected. Infectious disease specialists may be involved in cases of treatment-resistant or recurrent infections, especially when considering less common pathogens or antibiotic-resistant strains. In cases where STIs are suspected, consultation with a specialist in sexual health or genitourinary medicine may be warranted to ensure comprehensive evaluation and management. Collaboration between primary care clinicians and specialists ensures a multidisciplinary approach, optimizing patient care and outcomes in managing vaginitis.

Deterrence and Patient Education

Deterrence and patient education play crucial roles in preventing vaginitis and promoting vaginal health. Patients should be advised to maintain good hygiene by washing the genital area regularly with mild soap and water, avoiding douching, and wearing breathable cotton underwear. Safe sexual practices, including condom use and regular STI screenings, are essential. Patients should also be educated about the proper use of antibiotics, avoiding irritants such as scented feminine products, and the importance of a healthy lifestyle. Women should be taught proper toileting and wiping techniques to prevent recurrent infections. Patients should be reminded that douching also increases the risk of vaginitis. 

Understanding common symptoms, recognizing risk factors, and adhering to treatment plans are key components of patient education to ensure timely intervention and management of vaginitis. Providing educational resources empowers patients to take proactive steps in maintaining optimal vaginal health. Considering the anticipated global prevalence and economic impact of vaginitis in the coming decade, high-income countries must find better solutions and enhance the quality of care for affected women. With the growing interest in human microbiota, probiotic treatments have gained significant attention recently. As technology advances, a deeper understanding of the vaginal microbiome's composition and its preventive and therapeutic effects on vaginitis is expected to emerge.[33]

Pearls and Other Issues

Clinical pearls for vaginitis offer valuable insights and practical tips that enhance diagnostic accuracy and treatment efficacy. Key takeaways and best practices for managing vaginitis in clinical settings include the following:

  • Effective management of vaginitis hinges on accurate diagnosis, tailored treatment, and patient education.                                                                 
  • The diagnosis should be confirmed with laboratory tests to differentiate between bacterial, fungal, and protozoal infections.
  • The patient's history of recent antibiotic use, which can predispose to yeast infections, must be considered.
  • Sexual activity and the use of contraceptives must be inquired about, as these influence the vaginal flora.
  • Clinicians must diligently differentiate vaginitis from other gynecological conditions to avoid misdiagnosis pitfalls.
  • Treatment should address the underlying cause, and follow-up appointments ensure treatment efficacy and patient compliance.
  • Sexually active patients with vaginitis symptoms should be screened for STIs.
  • Even if symptoms improve early, the importance of completing prescribed treatments should be emphasized.
  • Coexisting conditions, such as diabetes mellitus, which can predispose patients to recurrent vaginitis, should be monitored and managed.
  • Patients should have follow-ups to ensure symptom resolution and address any ongoing concerns.
  • Recurrent infections, which may indicate an underlying condition or the need for a longer treatment course, should be checked for.
  • Appropriate disposition, including hospitalization or specialist referral, may be necessary in severe or complicated cases.
  • Preventive measures, such as practicing good hygiene, safe sexual practices, and avoiding douching, can help reduce the risk of vaginitis. Patient education is crucial.
  • Addressing hormonal imbalances and undergoing regular screenings can aid in prevention and improve patient outcomes.

Enhancing Healthcare Team Outcomes

A collaborative approach among healthcare professionals is essential for patient-centered care and optimal outcomes when managing vaginitis. Clinicians lead diagnosis and treatment planning, whereas advanced care practitioners provide primary care services and assist with assessments and education. Nurses offer hands-on care, patient advocacy, and medication administration, whereas pharmacists ensure safe medication use and provide medication counseling. Pharmacists should also educate women on the proper use of over-the-counter products and when to see a healthcare provider.[34][35] 

Effective interprofessional communication facilitates information sharing and care coordination, ensuring seamless transitions and holistic care. Upholding ethical standards, such as informed consent and patient autonomy, while coordinating services to optimize resources and minimize duplication, is paramount. These efforts enhance patient safety, outcomes, and overall team performance in the management of vaginitis.


Details

Author

Karen Carlson

Updated:

1/19/2025 10:39:26 PM

Looking for an easier read?

Click here for a simplified version

References


[1]

Leeper C, Lutzkanin A 3rd. Infections During Pregnancy. Primary care. 2018 Sep:45(3):567-586. doi: 10.1016/j.pop.2018.05.013. Epub 2018 Jul 9     [PubMed PMID: 30115342]


[2]

Amabebe E, Anumba DOC. The Vaginal Microenvironment: The Physiologic Role of Lactobacilli. Frontiers in medicine. 2018:5():181. doi: 10.3389/fmed.2018.00181. Epub 2018 Jun 13     [PubMed PMID: 29951482]


[3]

Saraf VS, Sheikh SA, Ahmad A, Gillevet PM, Bokhari H, Javed S. Vaginal microbiome: normalcy vs dysbiosis. Archives of microbiology. 2021 Sep:203(7):3793-3802. doi: 10.1007/s00203-021-02414-3. Epub 2021 Jun 13     [PubMed PMID: 34120200]


[4]

Kaambo E, Africa C, Chambuso R, Passmore JS. Vaginal Microbiomes Associated With Aerobic Vaginitis and Bacterial Vaginosis. Frontiers in public health. 2018:6():78. doi: 10.3389/fpubh.2018.00078. Epub 2018 Mar 26     [PubMed PMID: 29632854]


[5]

Kaambo E, Africa CWJ. The Threat of Aerobic Vaginitis to Pregnancy and Neonatal Morbidity. African journal of reproductive health. 2017 Jun:21(2):108-118     [PubMed PMID: 29624945]


[6]

Anahtar MN, Gootenberg DB, Mitchell CM, Kwon DS. Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell host & microbe. 2018 Feb 14:23(2):159-168. doi: 10.1016/j.chom.2018.01.013. Epub     [PubMed PMID: 29447695]


[7]

Xiaoming W, Jing L, Yuchen P, Huili L, Miao Z, Jing S. Characteristics of the vaginal microbiomes in prepubertal girls with and without vulvovaginitis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2021 Jun:40(6):1253-1261. doi: 10.1007/s10096-021-04152-2. Epub 2021 Jan 16     [PubMed PMID: 33452946]


[8]

Bagnall P, Rizzolo D. Bacterial vaginosis: A practical review. JAAPA : official journal of the American Academy of Physician Assistants. 2017 Dec:30(12):15-21. doi: 10.1097/01.JAA.0000526770.60197.fa. Epub     [PubMed PMID: 29135564]


[9]

Abdool Karim SS, Passmore JS, Baxter C. The microbiome and HIV prevention strategies in women. Current opinion in HIV and AIDS. 2018 Jan:13(1):81-87. doi: 10.1097/COH.0000000000000431. Epub     [PubMed PMID: 29059077]

Level 3 (low-level) evidence

[10]

Itriyeva K. Evaluation of vulvovaginitis in the adolescent patient. Current problems in pediatric and adolescent health care. 2020 Jul:50(7):100836. doi: 10.1016/j.cppeds.2020.100836. Epub 2020 Aug 8     [PubMed PMID: 32778468]


[11]

Shroff S. Infectious Vaginitis, Cervicitis, and Pelvic Inflammatory Disease. The Medical clinics of North America. 2023 Mar:107(2):299-315. doi: 10.1016/j.mcna.2022.10.009. Epub 2022 Dec 26     [PubMed PMID: 36759099]


[12]

Chen Y, Bruning E, Rubino J, Eder SE. Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. Women's health (London, England). 2017 Dec:13(3):58-67. doi: 10.1177/1745505717731011. Epub 2017 Sep 22     [PubMed PMID: 28934912]


[13]

Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Annals of epidemiology. 2017 Sep:27(9):575-582.e3. doi: 10.1016/j.annepidem.2017.08.010. Epub 2017 Aug 15     [PubMed PMID: 28927765]


[14]

Neal CM, Kus LH, Eckert LO, Peipert JF. Noncandidal vaginitis: a comprehensive approach to diagnosis and management. American journal of obstetrics and gynecology. 2020 Feb:222(2):114-122. doi: 10.1016/j.ajog.2019.09.001. Epub 2019 Sep 9     [PubMed PMID: 31513780]


[15]

Van Gerwen OT, Opsteen SA, Graves KJ, Muzny CA. Trichomoniasis. Infectious disease clinics of North America. 2023 Jun:37(2):245-265. doi: 10.1016/j.idc.2023.02.001. Epub 2023 Mar 31     [PubMed PMID: 37005163]


[16]

Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. Obstetrics and gynecology. 2011 Apr:117(4):850-855. doi: 10.1097/AOG.0b013e3182117c9e. Epub     [PubMed PMID: 21422855]


[17]

Marnach ML, Wygant JN, Casey PM. Evaluation and Management of Vaginitis. Mayo Clinic proceedings. 2022 Feb:97(2):347-358. doi: 10.1016/j.mayocp.2021.09.022. Epub     [PubMed PMID: 35120697]

Level 3 (low-level) evidence

[18]

Mitchell CM. Assessment and Treatment of Vaginitis. Obstetrics and gynecology. 2024 Dec 1:144(6):765-781. doi: 10.1097/AOG.0000000000005673. Epub 2024 Jul 11     [PubMed PMID: 38991218]


[19]

Tumietto F, Posteraro B, Sanguinetti M. Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. Future microbiology. 2019 Nov:14():1349-1355. doi: 10.2217/fmb-2019-0189. Epub 2019 Dec 17     [PubMed PMID: 31845594]


[20]

Qi W, Li H, Wang C, Li H, Zhang B, Dong M, Fan A, Han C, Xue F. Recent Advances in Presentation, Diagnosis and Treatment for Mixed Vaginitis. Frontiers in cellular and infection microbiology. 2021:11():759795. doi: 10.3389/fcimb.2021.759795. Epub 2021 Nov 2     [PubMed PMID: 34796129]

Level 2 (mid-level) evidence

[21]

Shen L, Zhang W, Yuan Y, Zhu W, Shang A. Vaginal microecological characteristics of women in different physiological and pathological period. Frontiers in cellular and infection microbiology. 2022:12():959793. doi: 10.3389/fcimb.2022.959793. Epub 2022 Jul 22     [PubMed PMID: 35937699]

Level 2 (mid-level) evidence

[22]

. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstetrics and gynecology. 2020 Jan:135(1):e1-e17. doi: 10.1097/AOG.0000000000003604. Epub     [PubMed PMID: 31856123]


[23]

Vieira-Baptista P, Grincevičienė Š, Oliveira C, Fonseca-Moutinho J, Cherey F, Stockdale CK. The International Society for the Study of Vulvovaginal Disease Vaginal Wet Mount Microscopy Guidelines: How to Perform, Applications, and Interpretation. Journal of lower genital tract disease. 2021 Apr 1:25(2):172-180. doi: 10.1097/LGT.0000000000000595. Epub     [PubMed PMID: 33631782]


[24]

Leclair C, Stenson A. Common Causes of Vaginitis. JAMA. 2022 Jun 14:327(22):2238-2239. doi: 10.1001/jama.2022.6375. Epub     [PubMed PMID: 35699716]


[25]

Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. International journal of STD & AIDS. 2018 Nov:29(13):1258-1272. doi: 10.1177/0956462418785451. Epub 2018 Jul 27     [PubMed PMID: 30049258]


[26]

Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert opinion on pharmacotherapy. 2018 Jun:19(9):971-977. doi: 10.1080/14656566.2018.1476490. Epub 2018 Jun 22     [PubMed PMID: 29932786]

Level 3 (low-level) evidence

[27]

Paladine HL, Desai UA. Vaginitis: Diagnosis and Treatment. American family physician. 2018 Mar 1:97(5):321-329     [PubMed PMID: 29671516]


[28]

Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023 Feb 7:329(5):405-420. doi: 10.1001/jama.2022.24140. Epub     [PubMed PMID: 36749328]


[29]

Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2021 Jul 23:70(4):1-187. doi: 10.15585/mmwr.rr7004a1. Epub 2021 Jul 23     [PubMed PMID: 34292926]


[30]

Cagnacci A, Xholli A, Venier M. Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use. Patient preference and adherence. 2020:14():55-62. doi: 10.2147/PPA.S203614. Epub 2020 Jan 10     [PubMed PMID: 32021117]


[31]

Liu EW, Workowski KA, Taouk LH, Schulkin J, Secor WE, Jones JL. Survey of Obstetrician-gynecologists in the United States About Trichomoniasis, 2016. Sexually transmitted diseases. 2019 Jan:46(1):9-17. doi: 10.1097/OLQ.0000000000000893. Epub     [PubMed PMID: 29994936]

Level 3 (low-level) evidence

[32]

Lee A, Kim TH, Lee HH, Kim YS, Enkhbold T, Lee B, Park YJ, Song K. Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials. Journal of menopausal medicine. 2018 Apr:24(1):1-10. doi: 10.6118/jmm.2018.24.1.1. Epub 2018 Apr 30     [PubMed PMID: 29765921]

Level 1 (high-level) evidence

[33]

Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, Li Y. Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy. Frontiers in cellular and infection microbiology. 2023:13():1123026. doi: 10.3389/fcimb.2023.1123026. Epub 2023 Feb 3     [PubMed PMID: 36816582]

Level 2 (mid-level) evidence

[34]

Lamont RF, Keelan JA, Larsson PG, Jørgensen JS. The treatment of bacterial vaginosis in pregnancy with clindamycin to reduce the risk of infection-related preterm birth: a response to the Danish Society of Obstetrics and Gynecology guideline group's clinical recommendations. Acta obstetricia et gynecologica Scandinavica. 2017 Feb:96(2):139-143. doi: 10.1111/aogs.13065. Epub 2017 Jan 13     [PubMed PMID: 27874978]


[35]

Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR, Secor WE, Sobel JD, Workowski KA. A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Dec 15:61 Suppl 8(Suppl 8):S837-48. doi: 10.1093/cid/civ738. Epub     [PubMed PMID: 26602621]